|Bid||39.50 x 1100|
|Ask||41.80 x 1000|
|Day's Range||38.02 - 41.85|
|52 Week Range||27.04 - 49.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
Guardant Health Inc. reported earnings late Monday that missed Wall Street profit expectations but beat on sales. It was the company's first earnings since its initial public offering earlier this year. Guardant reported third-quarter net losses of $24.5 million, or $1.94 a share, compared with losses of $33.3 million, or $2.76 a share, in the year-ago period. Revenue rose to $21.7 million from $11.1 million in the year-ago period. The five analysts surveyed by FactSet had estimated losses of 29 cents a share on revenue of $17.4 million. For the fourth quarter, analysts model losses of 32 cents a share on sales of $21.2 million. Guardant said it expects full-year 2018 revenue of $82 million to $84 million; the FactSet consensus is for revenue of $74.4 million. Guardant stock closed down roughly 10% in Monday trading, with the S&P 500 index falling 1.7%.
SoftBank's Vision Fund portfolio includes a little of everything, from startups that send satellites to space, to one that helps humans walk dogs. Here's what it means for the market.
Nearly half of the 22 U.S. IPOs in October priced below their range, according to Renaissance Capital, which manages exchange-traded funds made up of IPO stocks. Several more were postponed.
Small VistaGen is building a portfolio of drugs aimed at depression and other mental health conditions, while giant Gilead gets a lower effective tax rate — all that and more in our Health Care Digest.
Only eight of the Bay Area's unicorns have gone public this year. Meanwhile, 24 new ones have been born. Here's a look at all of them.
The startup’s cancer tests help match patients with the right treatments. It also has even bigger ambitions: to use its tests to find cancer recurrences, and even for early detection of cancers.
Shares of Guardant Health Inc. soared in their public debut Thursday, as they opened 46% above the initial public offering price, which was well above the expected range. The first trade for the cancer detection and treatment company's stock was at $27.75 at 10:48 a.m. ET for 1.7 million shares. That compares with the IPO price of $19, which was above the expected range of $15 to $17. The stock has extended gains since then, to trade up 51%. The company raised $237.5 million with the IPO, which values the company at $1.6 billion. Guardant is going public at a time that the Renaissance IPO ETF has slipped 0.9% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 7.5% and the S&P 500 has advanced 7.1%.
Guardant Health Inc. said Thursday its initial public offering of 12.5 million shares priced at $19 a share, above the expected range of $15 to $17 a share, to raise $237.5 million. If the underwriters exercise all the options granted to buy additional shares, oncology company could raise up to $273.1 million. The IPO pricing values the Redwood City, Calif.-based company at $1.59 billion. The company had a net loss of $83.2 million on revenue of $49.8 million in 2017, compared with a loss of $46.1 million and revenue of $25.2 million in 2016. The stock is expected to begin trading Thursday on the Nasdaq under the ticker symbol "GH." The company is going public at a time that the Renaissance IPO ETF has gained 5.0% year to date and the S&P 500 has gained 9.4%.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Upwork Inc. (UPWK) will issue nearly 12.3 million shares between $10 and $12 Wednesday on the Nasdaq. Upwork’s online platform ...